Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332
Ullrich et al., bioRxiv, doi:10.1101/2021.11.28.4702264 (Preprint) (In Vitro)
Ullrich et al., Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332, bioRxiv, doi:10.1101/2021.11.28.4702264 (Preprint) (In Vitro)
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Vitro study showing that PF-07321332 maintains efficacy against variants C.37 lambda, B.1.1.318, B.1.2, B.1.351 beta, and P.2 zeta.
Ullrich et al., 30 Nov 2021, preprint, 4 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2021.11.28.470226; this version posted November 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332 Sven Ullrich, Kasuni B. Ekanayake, Gottfried Otting, Christoph Nitsche* Research School of Chemistry, Australian National University, Canberra, ACT 2601, Australia *christoph.nitsche@anu.edu.au Graphical Abstract Keywords SARS-CoV-2, main protease, variants, PF-07321332, inhibitors Abstract The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of available vaccines. Specific antiviral agents are keenly anticipated but their efficacy may also be compromised in emerging variants. One of the most attractive coronaviral drug targets is the main protease (Mpro). A promising Mpro inhibitor of clinical relevance is the peptidomimetic PF-07321332. We expressed Mpro of five SARS-CoV-2 lineages (C.37 Lambda, B.1.1.318, B.1.2, B.1.351 Beta, P.2 Zeta), each of which carries a strongly prevalent missense mutation (G15S, T21I, L89F, K90R, L205V). Enzyme kinetics showed that these Mpro variants are similarly catalytically competent as the wildtype. We show that PF-07321332 has similar potency against the variants as against the wildtype. Our in vitro data suggest that the efficacy of specific Mpro inhibitors such as PF-07321332 is not compromised in current COVID-19 variants. 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.11.28.470226; this version posted November 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Since its emergence in late 2019,1 COVID-19 has significantly impacted on societies worldwide.2 More than 5 million deaths have been attributed to COVID-19, with the number of confirmed SARS-CoV-2 infections surpassing 250 million.3 The outbreak of SARS-CoV-2 prompted multiple successful vaccine development campaigns.4 Currently approved vaccines, such as viral vector or mRNA vaccines, successfully limited the pandemic’s impact on global health.5, 6 Most COVID-19 vaccines function by stimulating an immune response against the SARS-CoV-2 spike protein (S)7-9 but, as the spike gene has gathered pronounced genetic variability,10, 11 it is a common concern that the effectiveness of existing vaccines may be affected by those variants of SARS-CoV-2.5, 6, 10, 12 At the time of writing, the World Health Organization (WHO) lists four variants of concern (VOC; Alpha, Beta, Gamma, Delta) and two variants of interest (VOI; Lambda, Mu).13 A possible adjustment of the vaccines to currently circulating lineages of SARS-CoV-2 is being investigated.14-16 It is clear that the deployment of vaccines remains the best public health measure to control the spread of SARSCoV-2 and the severe health effects of COVID-19.17, 18 Complementary to preventive vaccines, antiviral drugs are urgently needed to combat COVID-19.19 Since the discovery of SARS-CoV-1 in 2003,20 several coronaviral drug targets have been identified,21..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit